The identification of antinuclear antibodies (ANA) is of central importance for the clinical diagnosis of connective tissue diseases (CTD), also called ANA-associated autoimmune rheumatic diseases (AARD), consisting of systemic lupus erythematosus (SLE), Sjögren's syndrome (SjS), systemic sclerosis (SSc), autoimmune myositis, and mixed connective tissue disease (MCTD).
EliA™ CTD assays offer numerous advantages. High sensitivity and specificity of results for the most clinically relevant markers that can be applied with confidence. Latest publications show that the addition of EliA CTD assays to conventional ANA detection by IFA improves the diagnostic accuracy significantly.1,2
The state-of-the-art portfolio for the diagnosis of CTD—quality you can trust
Most specific portfolio, helping you put the patient first
A portfolio optimized for routine testing laboratories
*The EliA CTD portfolio consists of EliA™ CTD Screen, EliA™ SymphonyS test, EliA dsDNA test, EliA™ Ro test, EliA™ Ro60 test, EliA™ Ro52 test, EliA™ La test, EliA™ U1RNP test, EliA™ RNP70 test, EliA SmDP-S test, EliA™ Scl-70S test, EliA™ CENP test, EliA™ Jo-1 test, EliA™ Rib-P test, EliA™ Fibrillarin test, EliA™ PCNA test, EliA™ RNA Pol III test, EliA™ PM-Scl test, EliA™ Mi-2 test and EliA™ DFS-70 test